VERTEX PHARMACEUTICALS/ US92532F1003 /
| 9/23/2024 6:02:50 PM | Chg. -5.50 | Volume | Bid8:30:00 PM | Ask8:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 415.50EUR | -1.31% | 5 Turnover: 2,077.50 |
-Bid Size: - | -Ask Size: - | 119.17 bill.EUR | - | - |
Assets
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 72.3000 | 133.2000 | 433.6000 | 696.9000 | 715.8120 | ||||||
| Intangible Assets | 518.7000 | 663.5000 | 663.5000 | 0.0000 | 29 | ||||||
| Long-Term Investments | 34.1000 | 34.1000 | 31.9000 | .1000 | - | ||||||
| Fixed Assets | - | - | - | - | 788.1680 | ||||||
| Inventories | 0.0000 | 112.4000 | 30.5000 | 14.1000 | 30.8480 | ||||||
| Accounts Receivable | 12.5000 | 183.1000 | 143.3000 | 85.5000 | 75.9640 | ||||||
| Cash and Cash Equivalents | 243.2000 | 475.3000 | 489.4000 | 569.3000 | 625.2590 | ||||||
| Current Assets | 1,057 | 1,331.2000 | 1,589.6000 | 1,588.6000 | 1,546.5110 | ||||||
| Total Assets | 1,725.4000 | 2,204.3000 | 2,759.3000 | 2,319 | 2,334.6790 | ||||||
Liabilities
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 35.9000 | 74.6000 | 101.3000 | 49.3000 | 71.1940 | ||||||
| Long-term debt | - | - | - | - | 792.9350 | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 280.6000 | ||||||
| Provisions | 160.3000 | 255.8000 | 281.1000 | - | - | ||||||
| Liabilities | 1,221.5000 | 1,275.8000 | 1,563.4000 | 962.6000 | 1,238.4960 | ||||||
| Share Capital | - | - | - | - | 2.3850 | ||||||
| Total Equity | 504 | 928.5000 | 1,195.9000 | 1,356.4000 | 1,096.1830 | ||||||
| Minority Interests | 0.0000 | 141.6000 | 196.7000 | 0.0000 | 21.1770 | ||||||
| Total liabilities equity | 1,725.4000 | 2,204.3000 | 2,759.3000 | 2,319 | 2,334.6790 | ||||||
Income Statement
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 143.4000 | 1,410.6000 | 1,527 | 1,212 | 580.4150 | ||||||
| Depreciation (total) | - | - | - | - | 63.2570 | ||||||
| Operating Result | -696.1000 | 113.8000 | 2.3000 | -903.4000 | -692.4120 | ||||||
| Interest Income | -17.3000 | -36.6000 | -14.8000 | -22.7000 | 72.8630 | ||||||
| Income Before Taxes | -754.6000 | 60.4000 | -12.4000 | -976.1000 | -734.8750 | ||||||
| Income Taxes | 0.0000 | 19.3000 | 38.8000 | -288.6000 | 6.9580 | ||||||
| Minority Interests Profit | 0.0000 | -11.6000 | -55.9000 | 242.5000 | 4.1900 | ||||||
| Net Income | -754.6000 | 29.6000 | -107 | -445 | -738.5550 | ||||||
Per Share
Cash Flow
|
2010 US GAAP in mill. USD |
2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -635.4000 | 143.7000 | 267.8000 | -51.6000 | -513.1990 | ||||||
| Cash Flow from Investing Activities | 7.3000 | 212.4000 | -425.8000 | -54.1000 | 73.9590 | ||||||
| Cash Flow from Financing | 425.1000 | -124.2000 | 172.2000 | 180.9000 | 497.3760 | ||||||
| Decrease / Increase in Cash | -203.5000 | 232.1000 | 14.1000 | 79.9000 | 55.9600 | ||||||
| Employees | 1,691 | 2,000 | 2,200 | 1,800 | 1,830 | ||||||
